This was of major interest, as it has not been investigated previously, and allows evaluation of the therapeutic potential of ML-SA1 and thus TRPML1 activation, to protect against AD-like endolysosomal phenotypes in a neuronal model system (Fig. 5A). This evidence concerns the gene MCOLN1 and Alzheimer disease.